Novo Nordisk and Mylan Pharmaceuticals, now part of Viatris, have settled their patent dispute over Novo’s blockbuster diabetes drug Ozempic.
The Danish company declined to comment on the terms of its confidential settlement agreement with Mylan on Monday. Novo has until 2032 before key US patents expire for its weight loss and diabetes drugs Wegovy and Ozempic, according to its 2023 full-year report. But when Mylan filed an application to market its generic version sooner, the company took legal action.
Novo filed a lawsuit against Mylan in 2022, which was eventually consolidated with similar cases against other generics makers in Delaware federal court.
On Oct. 2, Mylan and Novo told judge Colm Connolly that they had settled the dispute, and requested to dismiss the claims against Mylan. The companies also filed to withdraw Mylan’s ongoing case against one of Novo’s patents at the US Patent Office’s Patent Trial and Appeal Board.
Ozempic earned $14 billion in 2023 sales, and Wegovy generated another $4.6 billion.
Novo Nordisk’s fierce strategy around Ozempic and Wegovy has also included a litany of lawsuits against medical spas, weight loss clinics and telehealth companies marketing compounded versions of the semaglutide products.
Viatris did not respond to a request for comment.